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Synonymous or silent mutations are often overlooked in genetic analyses for disease-
causing mutations unless they are directly associated with potential splicing defects.
More recent studies, however, indicate that some synonymous single polynucleotide
polymorphisms (sSNPs) are associated with changes in protein expression, and in
some cases, protein folding and function. The impact of codon usage and mRNA
structural changes on protein translation rates and how they can affect protein
structure and function is just beginning to be appreciated. Examples are given here
that demonstrate how synonymous mutations alter the translational kinetics and
protein folding and/or function. The mechanism for how this occurs is based on a
model in which codon usage modulates the translational rate by introducing pauses
caused by nonoptimal or rare codons or by introducing changes in the mRNA
structure, and this in turn influences co-translational folding. Two examples of this
include the multidrug resistance protein (p-glycoprotein) and the cystic fibrosis
transmembrane conductance regulator gene (CFTR). CFTR is also used here as a
model to illustrate how synonymous mutations can be examined using in silico
predictive methods to identify which sSNPs have the potential to change protein
structure. The methodology described here can be used to help identify “non-silent”
synonymous mutations in other genes.
Keywords: Synonymous mutations, Single nucleotide polymorphism (SNP), Codon
usage, mRNA folding, Translation rate, in silico predictions, CFTRBackground
How silent polymorphisms can alter protein function
Synonymous single nucleotide polymorphisms (sSNPs) are a common feature of the
human genome, yet they are often overlooked in genetic analyses unless they are near
mRNA splice junctions. Nowadays, however, it has become increasingly clear that syn-
onymous mutations affect a number of other important cellular processes including
mRNA stability, and protein expression, folding and function [1–5]. While the role of
synonymous mutations in splicing defects is discussed elsewhere [4], here we focus on
how they influence these other processes. Our approach is to cite a number of exam-
ples that illustrate how synonymous mutations affect protein expression and function,© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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mutations.
Synonymous mutations have been shown to have effects in a number of diseases and
disorders including amyotrophic lateral sclerosis [6], increased pain sensitivity [7],
melanoma [8], schizophrenia [9], congenital heart disease [10], drug resistance [1], and
cystic fibrosis [11–13]. The details describing how these synonymous mutations have
their effects are described below.
Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is a rapidly progressive
fatal neurological disease with unclear etiology, although mutations in copper/zinc
superoxide dismutase (SOD1) are often associated with this disease. Michael Strong
and colleagues demonstrated that wild type SOD1 mRNA forms ribonucleoprotein
complexes with protein homogenates of neuronal tissues that stabilize the SOD1
mRNA, whereas mRNAs containing ALS missense mutations fail to form these
complexes and subsequently have less stable mRNA [6]. More interestingly, 4 silent
mutations that have been identified in ALS, Gly11 (C/T) [14], Ser60 (T/C;
rs373888553) [15], Thr117 (A/G) [16], and Ala141 (T/A; rs143100660) [15], and all of
these fail to form the ribonucleoprotein complexes in a manner similar to that seen for the
missense mutations [6]. The results from these studies indicate that loss of ribonucleopro-
tein binding results in a loss of mRNA stability. This illustrates an interesting and unex-
pected mechanism for how a synonymous mutation can affect protein expression levels.
Another example is found in the catechol-O-methyltransferase (COMT) gene. COMT
regulates pain perception and there are three haplotypes of the COMT gene that are as-
sociated with pain perception and developing temporomandibular joint disorder [17].
The three haplotypes are made up of four SNPs, one located in the promoter region,
and the other 3 in coding regions. Two are synonymous mutations, one at His62 (C/T;
rs4633) and another at Leu136 (C/G; rs4818), and the third is a missense mutation,
Val158Met (A/G; rs4680) [7]. Interestingly, the synonymous changes account for the
largest change in enzyme activity [7]. Diatchenko and colleagues focused on under-
standing how these synonymous mutations caused this loss of protein expression and
suggested that the differences were associated with mRNA secondary structural differ-
ences. To test this idea, they analyzed the mRNA secondary structures with the predict-
ive algorithms Mfold [18] and Afold [19]. This study also illustrated that the in silico
predictive methods for mRNA folding were confirmed by using site-directed mutagen-
esis to destabilize the predicted stem-loop structures. This manipulation destabilized
the predicted mRNA structures and resulted in an increase in protein and enzyme
activities, establishing that very stable mRNA secondary structures or those less likely
to unfold easily during translation are associated with less translated protein [19].
Even in the cancer genomics field, the role of synonymous mutations is now begin-
ning to be appreciated. Yardena Samuels and colleagues identified somatic mutations in
29 melanoma samples and found an interesting synonymous mutation in the Bcl-2-like
protein 12 (BCL2L12) gene that is as an anti-apoptotic factor (a C to T change at pos-
ition 51 (F17F)) [8]. This mutation leads to increased BCL2L12 mRNA and protein
levels. In characterizing this silent mutation, they found that this mutation occurred in
10 of 256 melanomas and that the elevations in mRNA and protein were not due to
splicing or translation changes or to changes in protein stability [8]. They found that
the mutation causes an accumulation in mRNA and protein and this promoted
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revealed the surprising finding that this synonymous mutation elevated mRNA levels
because of the differential targeting of wild type and mutant BCL2L12 by hsa-miR-671-
5p [8]. Interestingly, this type of effect was seen previously between synonymous muta-
tions and altered miRNA binding in the immunity-related GTPase family M (IRGM)
gene in Crohn’s disease [20].
An extremely thorough and interesting examination of the multidrug resistance 1
(MDR1) gene indicated that a synonymous SNP in this gene altered the drug and
inhibitor interactions in the gene product, P-glycoprotein [1]. P-glycoprotein is an
ATP-driven efflux pump that contributes to the multidrug resistance of cancer cells.
One particular synonymous SNP, C3435T, that was a part of a common haplotype was
associated with altered P-glycoprotein activity, and Chava Kimchi-Sarfaty analyzed this
mutation in detail in a broad range of cell lines and found no change in the level of
mRNA or protein in cells expressing this sSNP [1]. Their results, however, indicated
that this sSNP introduced a rare codon that altered the protein structure and function,
suggesting that translation was altered in the presence of the rare codon [1].
Perhaps the biggest reason that synonymous mutations are often overlooked is that
the vast majority of them, at least in most cases, are functionally neutral. In a study on
the human dopamine receptor D2 gene (DRD2), however, Gejman and colleagues
examined the functional properties of six known naturally occurring synonymous mu-
tations and surprisingly found that two had functional effects [9]. C957T was predicted
to alter the mRNA folding and this affected the mRNA stability and translation, and
importantly, a weakened response to dopamine-induced up-regulation of DRD2 [9].
The other synonymous mutation, G1101, did not have an effect on its own, but did
block the effects of the C957T mutation in the compound clone C957T/G1101A, dem-
onstrating that compound synonymous mutations can have unexpected consequences
[9]. Given that dopamine receptors are drug targets in the therapies of schizophrenia,
Parkinson’s and Huntington’s diseases [9], the importance in analyzing synonymous
mutations in this gene are obvious.
In human congenital heart disease, there are known mutations in cardiac-specific
transcription factor genes that impact protein function and the NK2 transcription factor
related, locus 5 gene (NKX2-5) provides a good example [10] of this. In NKX2-5, more
than 40 mutations have been identified in congestive heart failure patients. In a recent
study by Jurgen Borlak and colleagues, they analyzed cardiac biopsies of 28 patients
and identified a missense mutation in the NKX2-5 gene, A119E, along with two syn-
onymous mutations in-cis, c.543G > A (Q181Q) and c.63A > G (E21E) [10]. In vitro
functional analyses of the transcriptional activities of NKX2-5 using reporter plasmids
revealed that the A119E mutation resulted in as much as a 40 % reduction in activity,
and the addition of one or two synonymous mutations reduced the transcriptional
activities even further, suggesting that the synonymous mutations exacerbated the
phenotype of the missense A119E mutation [10]. Furthermore, using the Vienna RNA
folding algorithm for predicting mRNA structure, the authors found that the mRNA
secondary structure A119E mutant differed from wild type mRNA and that the
addition of the two synonymous mutations changed the structure even further [10].
These studies suggest that in some cases, synonymous mutations, while perhaps not
causal in and of themselves, can exacerbate the effects of a missense mutation [10].
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the F508del mutation
Prior studies by Bebok and colleagues found a similar effect in the CFTR gene [12]. We
examined a synonymous mutation in the most common mutation in the CFTR gene,
F508del, an out-of-frame deletion of phenylalanine that creates a synonymous mutation
for isoleucine at position 507 [12]. The human CFTR gene is particularly interesting
given that it codes for a protein that is highly sensitive to co-translational folding
[1, 21–23]. CFTR is a chloride and bicarbonate channel and key regulator of epi-
thelial functions [24–27]. Mutations in the CFTR gene lead to reduced or dysfunc-
tional CFTR protein and cause cystic fibrosis (CF), a generalized exocrinopathy
affecting multiple organs, but is most notably associated with lung disease [28].
The CFTR protein consists of a modular structure composed of two membrane-
spanning domains (MSD1 and MSD2, each comprising six transmembrane regions),
two nucleotide binding domains (NBD1 and NBD2), and a unique domain among
ATP-binding cassette (ABC) transporters called the regulatory domain (R) (Fig. 1) [24].
NBD1 and NBD2 participate in ATP binding and hydrolysis, while phosphorylation of
the R domain regulates channel gating [24]. Achieving the proper conformation of the
individual domains and interactions between these domains during protein synthesis is
critical for proper CFTR assembly [21, 22, 29, 30].
In order to reach its native tertiary structure, CFTR molecules undergo complex hier-
archical folding processes and posttranslational modifications [31–33]. The rate of wild
type and F508del CFTR translation in transfected human embryonic kidney (HEK 293)
cells has been calculated to be 2.7 residues per second based on an average translation
rate of 9.2 min [34]. This is slower compared to the average translation rate for other
proteins of 4–5 residues per second [35], suggesting that the CFTR translation rate is
unusual [21]. CFTR folding begins co-translationally [21], and is completed post-Fig. 1 A schematic model of the proposed structure of the cystic fibrosis transmembrane conductance
regulator (CFTR) using RasMol 2.7.5.2 (http://www.openrasmol.org) based on the RSCB PDB database
coordinates deposited for the human CFTR. The domains model are based on the data published by [57]
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loosely folded conformations co-translationally, but the final native tertiary structure
requires completion of the proper domain interactions [22]. CFTR domain assembly
has been estimated to take ~30–120 min [36].
Since CFTR translation and folding occur simultaneously, the choice of codons can
affect the translational kinetics during protein synthesis, but how that is linked to pro-
tein folding is just beginning to be appreciated [37]. Translational kinetics are believed
to be controlled, at least in part, by optimal and non-optimal codons (reviewed in [37]).
Optimal codons are postulated to be translated faster, whereas non-optimal are
translated slower, with non-optimal codons strategically placed to slow translation and
promote co-translational folding. Given the co-translation folding of CFTR and its slow
translation rate, we investigated how codon usage is predicted to influence CFTR’s
translational rate based on its utilization of optimal and non-optimal codons, and how
these changes are predicted to affect the co-translational folding within the individual
domains of CFTR. We also analyzed the known CFTR sSNPs that have been identified
in order to predict how they might affect the CFTR translational kinetics, mRNA struc-
ture, and the co-translational protein folding changes.
In silico predictive methods for identifying synonymous mutations that
impact protein function
Highly expressed genes often contain codons that are recognized by the most abundant
tRNAs and are considered optimal or fast since they are translated faster [38]. CFTR,
on the other hand, is expressed at extremely low amounts, and the translation rate ap-
pears to be slower than average [34]. Complex proteins generally utilize rare codons
that often localize at strategic domain-domain interfaces [39], and these rare codons
(or clusters of rare codons) promote ribosome pauses that may contribute to changes
in the folding pathways [39]. Since CFTR is a complex and multi-domain transmem-
brane protein with distinct transmembrane and cytoplasmic regions, we examined the
composition of codons used in human CFTR and determined whether the codons were
optimal or rare, and how their placement corresponded to predicted secondary
structures and CFTR domain organization.
In order to identify the predicted fast and slow translating regions in CFTR, we used
the relative synonymous codon usage (RSCU) method [40–43] to calculate the potential
codon impact on the translation rate (for methods, see Additional file 1). The analysis re-
veals that CFTR’s codon bias clearly consists of fast and slow translating regions, while
the N-terminal transmembrane MSD1 domain shows the highest content of slow translat-
ing codons (Fig. 2a, negative log RSCU numbers, that were compared to the entire CFTR
molecule that was normalized to 1). This is particularly evident at the end of MSD1,
which is critical to endoplasmic reticulum-associated degradation (ERAD) escape and also
the location responsible for binding to the CFTR misfolding corrector drug, VX-809 [44].
The log RSCU of the individual CFTR domains is shown in Fig. 2b. All of these regions
were compared to the entire CFTR molecule that was normalized to 1. The results shown
in Fig. 2b indicate that transmembrane MSD1 and MSD2 are predicted to be the slowest
translated regions in CFTR (~5 fold slower than the mean rate of CFTR). Other regions
predicted to be translated slowly include the sequences between MSD1 and NBD1
(MSD1/NBD1) and between MSD2 and NBD2 (MSD2/NBD2), and the carboxy-terminal
Fig. 2 a The distribution of optimal and rare codons in CFTR. The logarithm transformed moving median of
RSCU values (3-amino acid window) suggests the presence of slow/nonoptimal (negative log RSCU values) and
fast/optimal (positive) translated patches within the CFTR primary structure. The amino acid medians were
normalized to whole CFTR median RSCU (value 1). The CFTR domain location is marked above the graph. b
CFTR domains are translated with different rates as shown by their median RSCU values. The domain medians
were normalized to whole CFTR median RSCU (value 1). Significantly faster (>1) and slower (<1) translation of
the domains are marked with an *, while error bars represent the standard error of the mean (SEM)
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NBD1 and NBD2, the region between NBD1 and the R domain (NBD1/R), and the R do-
main are translated significantly faster than the CFTR average. The sequence between
NBD1 and R domain has the highest log RSCU value in CFTR (Fig. 2b). These data
predict that CFTR translation starts relatively fast, slows down while forming the MSD1
domain and then speeds up again during synthesis of the NBD1 and R domains. The
MSD2 domain translation is slow, and the slowest predicted translational rate is at the
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predicted to proceed quickly again, before slowing down again at the C-terminus (C’)
(Fig. 2b).
Both transmembrane domains (MSD1 and MSD2) are composed of membrane
spanning alpha helices connected by extracellular and cytosolic loops. Since both of
these regions appear to be translated more slowly than average for CFTR, we examined
these regions in more detail. As shown in Fig. 3a, almost the entire MSD1 is predicted
to be composed of relatively slow translating codons except for cytosolic loop 2 (CL2)
and external loop 3 (EL3). The slowest translating regions of MSD1 are helices 2 and 6
and external loop 1 (EL1) (Fig. 3a). The MSD2 codon bias is similar to MSD1 except
that the prediction is that helices 1’ and 4’ and external loops 4 and 6 (EL4 and EL6)
are translated faster than their counterparts in MSD1 (Fig. 3b). Interestingly in both
MSDs, the prediction is that the final external loops are translated very rapidly (EL3
and EL6), while the final helices are translated very slowly (helices 6 and 6’), suggesting
that the slowdown in translation is important at the end of both of these transmem-
brane domains.
Codon usage effects on the translational kinetics
There are 128 reported sSNPs in the human CFTR mRNA sequence and we analyzed
the RSCU value changes introduced by these sSNPs to see how these might affect the
translational kinetics (Additional file 2: Table S1). The median ΔRSCU value for the
SNPs was 0.075, and almost one-third of those analyzed (42 sSNPs) introduced either
significantly higher or lower RSCU values (highlighted in light grey in Additional file 2:
Table S1). To determine if these sSNPs were predicted to alter translational rate, we an-
alyzed each sSNP in 3–, 5-, and 10-amino acid RSCU windows as described in the
Additional file 1. As shown in Table 1, only 5 of the selected sSNPs (shown in bold in
Table 1) were predicted to alter the translational rate (one standard derivation above or
below the median for all 3 RSCU window analyses: c.1098A > G (G366 at the MSD1/
NBD1 interface); c1641A > T (T547 in NBD1); c.3472C > A (R1158 at the MSD2/NBD2
interface); c.3772 T > C (L1258 in NBD2); and c.3789 T > C (T1263 in NBD2) (Table 1).Fig. 3 The relative translation rate of the subdomains within MSD1 (a) and MSD2 (b). The subdomains of
MSD1 and MSD2 medians were normalized to whole CFTR median RSCU (value 1)
Table 1 sSNPs selected significant change in local codon bias motifs analyzed for 3-, 5- and 10-aa
clusters
sSNP CFTR domain Impact on
CFTR
translation
Significant RSCU change when analyzed in
3 aa 5 aa 10 aa
c.333G > A (P111) MSD1 (EL1) ↑ − + +
c.612 T > G (A204) MSD1 (helix 3) ↓ + − +
c.888 T > C (T296) MSD1 (CL2) ↓ + + −
c.981A > G (L327) MSD1 (helix 5) ↑ + − +
c.1074A > G (V358) MSD1/NBD1 ↑ + + −
c.1098A > G (G366) MSD1/NBD1 ↓ + + +
c.1164G > T (T388) MSD1/NBD1 ↑ + + −
c.1641A > T (T547) NBD1 ↓ + + +
c.1734A > G (L578) NBD1 ↑ + − +
c.2241G > A (A747) R ↑ − + +
c.2373A > G (T791) R ↓ + − +
c.2805A > G (L935) MSD2 (CL3) ↑ + + −
c.2907A > G (A969) MSD2 (CL3) ↓ + + −
c.3472C > A (R1158) MSD2/NBD2 ↑ + + +
c.3772 T > C (L1258) NBD2 ↑ + + +
c.3780A > G (L1260) NBD2 ↑ − + +
c.3789 T > C (T1263) NBD2 ↓ + + +
c.3897A > G (T1299) NBD2 ↓ + + −
Bartoszewski et al. Cellular & Molecular Biology Letters  (2016) 21:23 Page 8 of 13The other sSNPs listed in Table 1 showed effects in at least 2 of the 3 RSCU windows,
and depending on their location, could potentially affect the CFTR translational
kinetics.
Role of sSNPs in mRNA structural changes
The sSNP location within the domain, however, may not be the only decisive factor that
affects protein folding. Here we examine how codon usage changes could potentially alter
mRNA structure given that mRNA structural changes can affect the translational rate and
protein function [12, 13]. Using RNAsnp software [45, 46] to determine if any of the SNPs
could potentially influence CFTR mRNA structure (Additional file 3: Table S2), 8 SNPs
were identified as potential candidates. All of the identified 8 SNPs introduced changes in
the mRNA secondary structure by introducing hairpin turns, or by reorganizing or
removing them (shown in Additional file 4: Figure S1).
Predicted pathogenicity of the sSNPs using CADD
In the third type of analysis, we used a recently described tool for estimating the rela-
tive pathogenicity of human genetic variants based on the combined annotation
dependent depletion (CADD) method [47]. CADD estimates the relative pathogenicity
of variants based on annotations from a variety of sources and combining them into a
single measure that is expressed as a C-score [47]. The calculated C-scores resemble re-
sults from both conservation-based metrics and subset-relevant functional metrics.
Interestingly, the sSNP distribution in CFTR is characterized by significantly higher
average C-scores than observed in whole genome SNP distribution (Additional file 5:
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significantly higher than whole genome sSNP mean (6.36866 + 3.701498 = 10.07) [47],
and this led to the initial selection of 47 SNPs. (Additional file 5: Figure S2; Additional
file 6: Table S3). Interestingly, 4 of these sSNPs also showed up in the mRNA structural
changes analyses, and one of these showed up in all 3 analyses, c.3472C > A (R1158),
that is in the MSD2/NBD2 interface (Table 2).
Translation rates and protein folding
CFTR fits well into the classic model of protein folding that suggests that the trans-
membrane regions are translated slower than cytosolic regions. Indeed, if one takes a
closer look at the composition of the CFTR transmembrane domains (Fig. 3), it is clear
that the helixes are formed very slowly, particularly as the amino acids leave the trans-
membrane region. MSD2 is formed slightly faster than MSD1 and both of these do-
mains share common features. The last external loops of these transmembrane
domains (EL3 and EL6) contain optimal codons whereas the last helices (6 and 6′), as
well as the interface between the membrane spanning domains and the NBDs (MSD1/
NBD1 and MSD2/NBD2) are composed of rare codons. It is clear that MSD1 formation
and cytosolic loop assembly are crucial for both co- and posttranslational CFTR fold-
ing. Hence, the changes in codon bias in these regions, especially at helices entering or
leaving the membrane introduced by mutations or sSNPs could affect CFTR folding
efficiency significantly and thus the levels and/or function of the mature protein.
Translation pauses are a general strategy that is employed in the co-translational
folding of individual domains in a multi-domain protein. The time separation provided
by the pause allows completion of the processes without interruption, thus helping to
avoid problems in protein folding and aggregation [48]. Interfering with this process
with changing codons introduced by sSNPs can lead to downstream effects. For ex-
ample, changing codons has been shown in a number of cases to alter protein structure
and function [1, 3, 39, 49, 50]. SNPs have been proposed to lead to alternate folding
pathways through ribosome stalling, a lower concentration of cognate tRNAs (codon
usage), or through alteration of the RNA structure [12, 13, 39, 51]. Altered RNA
secondary structures have been shown to influence the length of the pause cycles and
the rate of translation [52]. Thus, mRNA structural-related changes in translational
dynamics likely influence membrane integration and co-translational folding of multi-
spanning membrane proteins like CFTR [21, 53]. Our previous studies demonstrate
that mRNA structural changes associated with the I507 SNP introduced by the F508del
CFTR mutation results in a decreased translational rate of F508del CFTR [12]. Further-
more, a synonymous single nucleotide variant of the F508del CFTR (Ile507ATC), thatTable 2 sSNPs selected as significant by at least 2 independent analysis types (RSCU, mRNA
structure and CADD)
sSNP CFTR domain RSCU mRNA structure CADD
c.612 T > G (A204) MSD1
(helix 3)
+ + −
c.3345C > A (T1115) MSD2
(helix 5′)
− + +
c.3472C > A (R1158) MSD2/NBD2 + + +
c.3504C > T (D1168) MSD2/NBD2 − + +
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type-like CFTR mRNA structure and enhanced expression levels when compared with
native F508del CFTR [12]. More importantly, this substitution also affects the function
of the protein [13] and sensitivity to drugs [11].
CFTR folding appears to be extremely complex (reviewed in [36]). The slow predicted
translation rate for the MSDs makes sense given that homology models predict a complex
domain swap structure of two six-spanning helical bundles containing transmembranes
1–2, 9–12 and transmembranes 7–8, 3–6 that are twisted around a central ion-
conducting pore [36, 54]. Furthermore, CFTR transmembrane helices contain a number
of charged residues which may be important for this complex arrangement of TMDs, and
this in combination with the hydrophobic amino acids and the non-optimal codons could
slow down translation, and in doing so, provide the necessary time for the proper
assembly for this complex, pore-forming structure. Hopefully, this type of in silico analysis
and discussion provides a framework for where to begin analyzing synonymous polymor-
phisms and establishes the concept that these types of changes should not be overlooked
in future genetic screens.
Prospects
How codon usage and mRNA structure affect protein translational rates are just beginning
to be understood. Algorithms for mRNA structure predictions identify the lowest energy
structure among a mixture of structures that certainly exist in equilibrium [45, 55, 56]. Even
if the correct structure is identified, supporting biochemical evidence by circular dichroism
studies or mRNA folding assays such as the SHAPE assay need to be performed to confirm
the predictions [12]. This also means that clonal cell lines have to be established to test for
these effects, and the mRNA and protein expression levels and stabilities need to be tested.
In the case of I507-ATC- >ATT, we found this synonymous codon change altered the
mRNA structure and protein expression levels [12], increased the thermal stability and
channel gating properties as monitored whole-cell patch-clamp recordings and single
channel recordings, respectively [13], and altered the channel’s sensitivity to drugs [11]. In
this particular case, the I507 sSNP exacerbated the effect of the F508del mutation. This
suggests the intriguing possibility that other silent polymorphisms have the potential to
exacerbate or even mollify disease-causing mutations, or in extreme cases, even be disease-
causing themselves. Given the large number of silent polymorphisms found in most genes,
and the amount of work required to determine if a polymorphism actually has any effect,
bioinformatics approaches such as the ones described here will continue to be an important
aspect of future studies that determine which silent polymorphisms alter protein expression
and/or function.
Conclusions
An interesting aspect of these studies is the fact that the individual rates of translation of
the different domains of CFTR are predicted to be very different and are consistent with
the idea that the domains fold co-translationally. How these sSNPs actually affect the
translational kinetics, however, can only be determined experimentally. An intriguing
possibility, however, is that sSNPs, especially in combination with known mutations, could
either exacerbate or mollify the severity of the mutation through their influence on the
translational kinetics of the domain itself or within a domain-domain interface.
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Additional file 1: Supplementary methods. (DOCX 36 kb)
Additional file 2: Table S1. SNPs effects on CFTR RSCU The SNPs with significant ΔRSCU values are marked grey.
Depending on database coverage the dbSNP database (rs#) and CFTR mutation database identifiers for SNPs were
used. (XLSX 30 kb)
Additional file 3: Table S2. SNPs effects on CFTR mRNA secondary structure. The SNPs with significant p - values
(<0.2) are marked grey. Furthermore, sSNPs with p - value p < 0.05 in at least one analysis mode and p < 0.2 in the
second analysis mode were further considered (marked bold) [8, 9]. (XLSX 37 kb)
Additional file 4: Figure S1. Predicted mRNA structures illustrating how the sSNPs affect the local mRNA
structure. The wild type sequence is shown in the left panel and sSNP in the right. The structural models were
obtained with RNAsnp software, within a 200 nt region centered around the sSNP. (TIF 5393 kb)
Additional file 5: Figure S2. A. Comparison of C-score values distributions calculated for CFTR sSNPs compared
to the entire human genome. Median values are marked with solid lines, error bars represent standard deviations.
B. Distribution of sSNPs related C-score values within CFTR primary structure, the ones above solid line represent
values that were significantly higher than whole genome sSNP mean + SD (6.36866 + 3.701498 = 10.07), whereas
the sSNPs with top 25 % C-score values are marked with solid black triangles. The CFTR domain location is marked
above the graph. (TIF 1790 kb)
Additional file 6: Table S3. CADD analysis of CFTR SNPs. SNPs that may affect splicing are marked bold. SNPs
with C-score significantly higher than whole genome median are marked light grey, while SNPs with highest
quartile C-scores are marked dark grey. (XLSX 28 kb)
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